English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Summary  The thrombopoietin receptor agonist romiplostim is approved for second‐line use in chronic immune thrombocytopenia ( ITP ), but its effects in patients with  ITP  for ≤1 year are not well characterized. This analysis of pooled data from 9 studies included patients with  ITP  for ≤1 year ( n  =   311) or >1 year ( n  =   726) who failed first‐line treatments and received romiplostim, placebo or standard of care. In subgroup analysis by  ITP  duration, patient incidences for platelet response at ≥75% of measurements were higher for romiplostim [ ITP  ≤1 year: 74% (204/277);  ITP  >1 year: 71% (450/634)] than for placebo/standard of care [ ITP  ≤1 year: 18% (6/34);  ITP  >1 year: 9% (8/92)]. Of patients with ≥9 months on study, 16% with  ITP  ≤1 year and 6% with  ITP  >1 year discontinued romiplostim and maintained platelet counts ≥50 × 10 9 /l for ≥6 months without  ITP  treatment (treatment‐free remission). Independent of  ITP  duration, rates of serious adverse events and bleeding were lower with romiplostim than placebo/standard of care and thrombotic events occurred at similar rates. In this analysis, romiplostim and placebo/standard of care had similar safety profiles and romiplostim increased platelet counts in patients with either  ITP  ≤1 year or  ITP  >1 year, with more treatment‐free remission in those with  ITP  ≤1 year.

british journal of haematology

Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia ( ITP ) for up to 1 year and in those with chronic  ITP  for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies